Skip to main content
Premium Trial:

Request an Annual Quote

Purdue Group Describes Novel Mass Spec Protein Chip Technique

NEW YORK, Aug. 18 (GenomeWeb News) - Researchers at Purdue University are developing a protein biochip machine, the university said Aug. 14.

 

"This technique, when fully developed, will allow us to take hundreds of proteins from a cell without damaging them," R. Graham Cooks, a professor of analytical chemistry at Purdue, said in a statement. "We can then deposit these proteins in specific locations on a chip, where their functions can be analyzed quickly.

 

Cooks and colleagues described a part of this technique, a mass spec-based separation technique, in an article published in the Aug. 13 online edition of Science. The technique, called ion soft landing, involves modifying a mass spectrometer so it can collect proteins after separation by depositing the ions onto various locations on the chip's surface.  The process produces pure protein samples, the researchers said.

 

The article, by Zheng Ouang and colleagues, is entitled "Protein microarrays by Ion Soft Landing: Preparative Mass Spectrometry."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.